Current Drug Targets
Volume 22, 17 Issues, 2021
ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)
This journal supports open access
ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)
This journal supports open access
In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research
Contents
Current Drug Targets, Volume 10 - Number 10
First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dellAdulto) Multiple Myeloma Working Party Perspective
, 10(10): 906 - 922Pellegrino Musto, Fiorella D'Auria, Giuseppe Pietrantuono, Luca Baldini, Sara Bringhen, Tommaso Caravita, Francesco Di Raimondo, Fortunato Morabito, Massimo Offidani, Maria Teresa Petrucci, Patrizia Tosi, Francesca Gay, Michele Cavo, Mario Boccadoro and Antonio Palumbo
DOI: 10.2174/138945009789577936
Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
, 10(10): 923 - 936Antonio Gualberto and Michael Pollak
DOI: 10.2174/138945009789577945
Targeting Sarcomas: Novel Biological Agents and Future Perspectives
, 10(10): 937 - 949Devalingam Mahalingam, Alain Mita, Kamalesh Sankhala, Ronan Swords, Kevin Kelly, Francis Giles and Monica M. Mita
DOI: 10.2174/138945009789577990
Drug Targeting Through Pilosebaceous Route
, 10(10): 950 - 967Rashmi Chourasia and Sanjay K. Jain
DOI: 10.2174/138945009789577918
Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
, 10(10): 982 - 1000Vincenzo Emanuele Chiuri, Nicola Silvestris, Andrea Tinelli and Vito Lorusso
DOI: 10.2174/138945009789578007
Inflammatory Systemic Biomarkers in Setting Acute Coronary Syndromes - Effects of the Diurnal Variation
, 10(10): 1001 - 1008A. Dominguez-Rodriguez, P. Abreu-Gonzalez and J. C. Kaski
DOI: 10.2174/138945009789577963
The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis
, 10(10): 1009 - 1020Michael Myslobodsky
DOI: 10.2174/138945009789577927
Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model
, 10(10): 1021 - 1027F. Pastorino, D. Di Paolo, M. Loi, P. Becherini, I. Caffa, A. Zorzoli, D. Marimpietri, R. Carosio, P. Perri, P. G. Montaldo, C. Brignole, G. Pagnan, D. Ribatti, T. M. Allen and M. Ponzoni
DOI: 10.2174/138945009789577954
Down with the Erythropoietin. Long Live the Erythropoietin !
, 10(10): 1028 - 1032Michele Buemi, Antonio Lacquaniti, Davide Bolignano, Valeria Cernaro, Susanna Campo, Giovanni Grasso, Antoine Buemi, Valentina Donato and Alessio Sturiale
DOI: 10.2174/138945009789577981
Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient
, 10(10): 1033 - 1040F. Meriggi, B. Di Biasi, C. Abeni and A. Zaniboni
DOI: 10.2174/138945009789577891
Antiviral Agents for Influenza: Molecular Targets, Concerns of Resistance, and New Treatment Options
, 10(10): 1041 - 1048Helen C. Maltezou and Sotirios Tsiodras
DOI: 10.2174/138945009789577972
Editor-in-Chief
Francis J. Castellino
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
(USA)
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
COPE Compliant
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Drug Targets Journal was launched in 2000. Dr. Francis J. Castellino serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 2.63
Webmaster Contact: info@benthamscience.net